

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Equality and health inequalities assessment (EHIA)

Early and locally advanced breast cancer

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

Early and locally advanced breast cancer [NG101]

Section 1.3 Surgery to the breast.

STAGE 4. Development of guideline or topic area for update

NG101 Early and locally advanced breast cancer

Date of completion: 19/10/2023

Focus of guideline or update: Further surgery after breast conserving surgery based on tissue margins

4.1 From the evidence syntheses and the committee's considerations thereof, what were the main equality and health inequalities issues identified? Were any **further** potential issues identified (in addition to those identified during the scoping process) or any gaps in the evidence for any particular group?

1) Protected characteristics

No further potential issues were identified.

2) Socioeconomic status and deprivation

No further potential issues were identified.

3) Geographical area variation

The committee noted that there could be limitations with access to oncoplastic techniques. Oncoplastic surgery may not be available in some areas, and this could affect a person's decision about further surgery if they have concerns about post-surgery cosmesis.

4) Inclusion health and vulnerable groups

No further potential issues were identified.

4.2 How have the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the guideline or update and any draft recommendations?

The committee's discussion on these issues is included in the evidence review (in the section on the committee's discussion of the evidence).

The committee made a recommendation for a shared decision around whether to have further surgery for radial margins of less than 1mm for people with invasive breast cancer with or without DCIS or 2mm for people with DCIS without invasive cancer. They took care to include the person's preferences, which would be expected to facilitate a discussion of any equality issues that might impact on the individual's decision whether to have further surgery, as well as clinical factors. To facilitate this discussion they included cross references to the following: [enabling patients to actively participate in their care in the NICE guideline on patient experience in adult NHS services](#), and [communicating risks, benefits and consequences in the NICE guideline on shared decision making](#).

4.3 Could any draft recommendations potentially increase inequalities?

No

4.4 How has the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the development of any research recommendations?

No research recommendations were made.

4.5 Based on the equality and health inequalities issues identified in 2.2, 3.2 and 4.1, do you have representation from relevant stakeholder groups for the guideline or update consultation process, including groups who are known to be affected by these issues? If not, what plans are in place to ensure relevant stakeholders are represented and included?

Due to the large number of potential groups involved we plan to try to engage with people from relevant groups during consultation. We have a number of organisations registered for consultation who we will ask for feedback on our recommendations.

4.6 What questions will you ask at the stakeholder consultation about the impact of the guideline or update on equality and health inequalities?

DRAFT FOR CONSULTATION

We are going to ask the stakeholders if they are aware of any measures that have helped to address the health inequalities raised in the EHIA. We will ensure that any equalities related comments are discussed with the committee, and changes will be made to the recommendations, evidence review discussion or rationale where necessary.

Completed by developers Yolanda Martinez, Clare Dadswell and Marie Harrisingh

Date 7/10/2023

Approved by committee chair Adam Firth

Date 7/11/23

Approved by NICE quality assurance lead Kate Kelly

Date 10/11/23